Highlights from recent Life Science venture capital news.
Funding & Investment
July 19th, 2012 – Princeton, NJ
Agile Therapeutics raises $40 Million in a Series C Financing
Agile Therapeutics announced today that it has closed a $40 million Series C financing. The round was led by new investor Aisling Capital, LLC, who joins existing Agile investors including Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures, and Novitas Capital.
July 16th, 2012 – Cleveland, OH
Juventas Therapeutics Raises $22.2 Million Series B Financing
Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures. All previous venture firms, including Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners participated in the round. Also joining the syndicate are new investors Takeda Ventures, Venture Investors, Global Cardiovascular Innovation Center, Tri-State Growth Fund, Glengary and select angel investors.
July 18th, 2012 – San Diego, CA
Obalon Therapeutics Secures $16.5M Series C Financing
Obalon Therapeutics, Inc. announced it closed a $16.5 million Series C private equity financing, began enrolling patients in a U.S. clinical trial, received CE Mark approval and had weight loss data presented at the IFSO European Congress (International Federation for the Surgery of Obesity and Metabolic Disorders).
July 16th, 2012 – Stony Brook, NY
Coferon, Inc. Announces $12 Million Series B Financing
Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and Ascent Biomedical Ventures of New York, N.Y.
July 17th, 2012 – Strasbourg, France
Domain Therapeutics Closes €2M Funding
Domain Therapeutics, a Strasbourg, France-based biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs), has completed a €2m financing.
Half of the funds have been provided by new investor Seventure Partners and the other half has been committed by new investor SODIV and existing shareholders AIRFI, IP Growth, Auriga and Sam Eletr, the chairman of the company’s board.Yea
July 19th, 2012 – Redwood City, CA
J&J Acquires Developer of Insulin Patch Product
Johnson & Johnson’s (JNJ) LifeScan unit has acquired a closely held developer of a wearable insulin patch for people with diabetes.
LifeScan acquired Calibra Medical Inc., of Redwood City, Calif., on July 13, said LifeScan spokesman Dave Detmers.
Financial terms aren’t being disclosed. The insulin patch isn’t available yet, and LifeScan isn’t saying when it expects it to become available. The product must meet “a number of milestones” before it reaches market.
July 16th, 2012 – Foster City, CA
Acquisition of Navigenics Expands Life Technologies’ Capabilities in Diagnostics
Life Technologies Corporation (NASDAQ:LIFE – News) today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies’ first step in executing against a strategy to build out its molecular diagnostics business through internal development, partnerships and select acquisitions.
This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier
VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.